Full text is available at the source.
Research progress on gut microbiota in colorectal cancer immunotherapy
Advances in Understanding Gut Bacteria's Role in Colorectal Cancer Immunotherapy
AI simplified
Abstract
Immune checkpoint inhibitors (ICIs) have shown variable efficacy in treating colorectal cancer (CRC), influenced by gut microbiota.
- Interindividual variability in ICI responses has been observed in CRC patients.
- Certain bacterial species, like Lactobacillus paracasei and Fusobacterium nucleatum, may affect ICI efficacy through their impact on immune responses.
- Microbial metabolites, such as short-chain fatty acids, could enhance immune function and improve outcomes with ICIs.
- Potential interventions targeting the microbiome include combinations of probiotics and prebiotics, optimized antibiotic use, and refined fecal microbiota transplantation protocols.
- This review synthesizes current evidence to support the development of personalized immunotherapy strategies focused on microbiome modulation.
AI simplified